Ryan Allway October 6th, 2021 Psychedelics Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment Experience Vancouver, British Columbia–(Newsfile Corp. – October 6, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that... Read more
Ryan Allway October 5th, 2021 Psychedelics VANCOUVER, British Columbia, October 05, 2021–(BUSINESS WIRE)–REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company“) (CSE: CALM) (CSNX: CALM.CN) (OTC: RVLWF) is pleased to announce it has commenced trading in the United States on OTC Markets Group’s OTC Pink marketplace under the ticker symbol... Read more
Lobe Sciences to Present at the BioFuture 2021 & MoneyShow Virtual Expo Investor Conferences
October 5, 2021
Ryan Allway October 5th, 2021 Psychedelics Vancouver, British Columbia–(Newsfile Corp. – October 5, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) today announced that Philip Young, CEO and Director, will present virtually at the BioFuture 2021 Conference taking place October 5-6, 2021, and... Read more
Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development
Biotechnology October 1, 2021
Ryan Allway October 1st, 2021 Psychedelics TORONTO, October 01, 2021–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company“), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce: the addition of Dr. Amir Inamdar as its Chief Medical Officer for its European Operations, the addition of Dr.... Read more
Mydecine Completes Spin-Out of U.S. Cannabis Assets
October 1, 2021
Ryan Allway October 1st, 2021 Psychedelics DENVER, Oct. 01, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biopharmaceutical company focused on the treatment of mental health and addiction, today announced that it has completed its previously announced spin-out transaction (the “Transaction”)... Read more
Clearmind Medicine to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20
October 1, 2021
Ryan Allway October 1st, 2021 Psychedelics An expert panel will present and discuss new potential treatments for Alcohol Use Disorder and binge drinking TORONTO, Oct. 01, 2021 (GLOBE NEWSWIRE) — via InvestorWire – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on... Read more
Psychedelic Stock Review Initiates Coverage on Ehave Inc.
September 30, 2021
Ryan Allway September 30th, 2021 Psychedelics MIAMI, Sept. 30, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today the Psychedelic Stock Review has initiated coverage. “Ehave is about to release a number of digital... Read more
Clearmind Medicine To Fund Second R&D Partnership With Hebrew University’s Technology Transfer Company
September 27, 2021
Ryan Allway September 27th, 2021 Psychedelics Toronto, Ontario–(Newsfile Corp. – September 27, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce... Read more
Ketamine Offers Promise to Veterans with PTSD
September 24, 2021
Ryan Allway September 24th, 2021 App, Exclusive, Psychedelics, Top Story Post-traumatic stress disorder, or PTSD, is a common mental illness among veterans. According to the Department of Veteran Affairs, 11% to 30% of veterans who served in foreign wars experience PTSD, far higher than the estimated 6% of the... Read more
Ryan Allway September 23rd, 2021 Psychedelics Toronto, Ontario–(Newsfile Corp. – September 23, 2021) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“) a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs,... Read more
